Cappelli, Laura C. http://orcid.org/0000-0003-2795-7059
Reed, George
Pappas, Dimitrios A.
Kremer, Joel M.
Funding for this research was provided by:
Corrona Research Foundation
Article History
Received: 3 August 2023
Accepted: 28 September 2023
First Online: 19 October 2023
Declarations
:
: Laura C Cappelli received research funding from Bristol-Myers Squibb and has consulted for Bristol-Myers Squibb, Mallinckrodt, and Tremeau Pharmaceuticals. George Reed is a consultant for Corrona Research Foundation and for CorEvitas. Dimitrios Pappas has equity interests in and is an employee of CorEvitas (formerly known as Corrona), is a member of the Board of Directors of the Corrona Research Foundation (CRF), and has received honoraria/consulting fees from Novartis, Sanofi, Genentech, Roche, and Abbvie. Joel Kremer has an equity interest in CorEvitas and has consulted for Lilly.
: All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor approval and continuing review was obtained through a central Institutional Review Board (IRB) (New England Independent Review Board [NEIRB] No.120160610). For academic investigative sites that did not receive a waiver to use the central IRB, approval was obtained from the respective governing IRBs and documentation of approval was submitted to the Sponsor prior to initiating any study procedures. All registry subjects were required to provide written informed consent prior to participating. The study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.